|
For Regulated Markets |
| |
Therapeutic Category |
Product |
EUDMF/COS |
USDMF |
|
Antiurolithic |
Allopurinol |
R0-CEP 2008-017-Rev 00 |
DMF no 21239 |
|
Antidiabetic |
Gliclazide |
R0-CEP 2010-202-Rev 00 |
NA |
|
Glimepiride |
R0-CEP 2009-067-Rev 01 |
DMF no 22565 |
|
Antipsychotic |
Quetiapine Fumarate
|
* |
DMF no 25000 |
|
Antiglaucoma |
Betaxolol Hydrochloride |
R0 CEP 2011-031-Rev 00 |
DMF no 25301 |
|
Brimonidine Tartrate |
EUDMF Available |
DMF no 22166 |
|
Dorzolamide Hydrochloride |
* |
DMF no 23795 |
|
Brinzolamide |
* |
* |
|
Antiinflammatory
(Ophthalmic) |
Bromfenac Sodium |
* |
DMF no 25245 |
|
Antiallergic,
Antihistaminic |
Olopatadine Hydrochloride
|
* |
DMF no 24106 |
|
NSAID (Ophthalmic) |
Nepafenac
|
* |
* |
|
Antispasmodic |
Dicycloverine Hydrochloride
|
R0-CEP 2008-281-Rev 00 |
DMF no 22295 |
|
Antiparkinsonian |
Rasagiline Mesylate
|
* |
* |
|
Antibacterial |
Ciprofloxacin Hydrochloride
|
R0-CEP2008-176-Rev 01 |
DMF no 21909 |
* Under filing
Disclaimer - The above products are under development or study for internal or experimental uses.
The products & their intermediates will not be sold in countries, in which they are protected by valid patents. None of the products mentioned above are offered for sale or supplied yet in the territories where they are under patent.
|
| |
|
For Emerging Markets |
| |
Therapeutic Category |
Product |
|
Anticonvulsant |
Pregabalin |
|
Lamotrigine |
|
Antilipemic |
Atorvastatin Calcium
|
|
Muscle Relaxant
(skeletal) |
Chlorzoxazone |
|
Mydriatic (ophthalmic) |
Homatropine Hydrobromide |
|
Antihypertensive |
Carvedilol |
|
Losartan Potassium |
|
Ramipril |
|
Antifungal |
Fluconazole |
|
Antihistaminic |
Cetirizine
Dihydrochloride |
|
Antidepressant |
Sertraline Hydrochloride |
|
Antidiabetic |
Glibenclamide |
|
Antiulcerative |
Omeprazole Pellets 7.5% /
8.5% (made to order) |
|
Vasodilator (peripheral,
cerebral) |
Cinnarizine |
Veterinary |
|
Anthelmintic |
Diminazene Diaceturate |
|
Oxyclozanide |
|
Antiprotozoal |
Ethopabate |
*Under filing
Disclaimer - The above products are under development or study for
internal or experimental uses.
The products & their intermediates will not be sold in countries, in
which they are protected by valid patents. None of the products
mentioned above are offered for sale or supplied yet in the
territories where they are under patent. |
| |
Products Under Development / Evaluation |
| |
Therapeutic Category |
Product |
|
Conjuctivitis |
Besifloxacin Hydrochloride |
|
Hyperuricemia |
Febuxostat |
|
Antihyperphosphatemic |
Sevelamer Carbonate |
|
Hypercholesterolaemia |
Rosuvastatin Calcium |
|
Antihypertensive |
Bosentan |
|
Allergic Rhinitis |
Azelastin Hydrochloride |
|
Bilastine |
|
Allergic Rhinitis, Urticaria |
Bepotastine Besylate |
|
Antihyperlipidemic |
Colesevelam HCl |
|
Anticonvulsant |
Rufinamide |
|
Analgesic, Anticonvulsant |
Lacosamide |
|
Analgesic |
Tapentadol Hydrochloride |
|
Antidiabetic |
Voglibose |
|
Antimalarial |
Lumifantrine |
|
Hypercholesterolemia |
Fenofibrate |
|
Hypnotic |
Propofol |
|
Antiemetic |
Domperidone |
|
Immuno modulator |
Imiquimod |
|
Disclaimer - The above products are under development or study for
internal or experimental uses and this list has no commercial purpose. The products & their intermediates will not be sold in countries, in
which they are protected by valid patents. None of the products
mentioned above are offered for sale or supplied yet. |
|
